SymBio Pharmaceuticals Limited
SYMQY · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Operating Activities | – | – | – | – |
| Net Income | -$3,806,957 | -$1,195,387 | $2,106,279 | $1,001,331 |
| Dep. & Amort. | $0 | $96,005 | $98,092 | $93,959 |
| Deferred Tax | $0 | $0 | -$790,099 | -$26,755 |
| Stock-Based Comp. | $93,409 | $82,497 | $104,731 | $124,270 |
| Change in WC | $263,074 | $1,068,000 | -$59,781 | -$1,066,669 |
| Other Non-Cash | $33,956 | -$245,800 | $155,019 | $13,906 |
| Operating Cash Flow | -$3,416,518 | -$194,685 | $1,614,241 | $140,042 |
| Investing Activities | – | – | – | – |
| PP&E Inv. | -$19,816 | -$204,000 | -$47,558 | -$63,837 |
| Net Acquisitions | $0 | $0 | $0 | $0 |
| Inv. Purchases | $0 | $0 | $0 | $0 |
| Inv. Sales/Matur. | $0 | $0 | $0 | $0 |
| Other Inv. Act. | $15,861 | -$172,696 | $431 | -$7,012 |
| Investing Cash Flow | -$3,955 | -$376,696 | -$47,127 | -$70,849 |
| Financing Activities | – | – | – | – |
| Debt Repay. | $0 | $0 | $0 | $0 |
| Stock Issued | $728,908 | $681,157 | $662,227 | $0 |
| Stock Repurch. | -$20,436 | $0 | -$48,002 | -$72,826 |
| Dividends Paid | $0 | $0 | $0 | $0 |
| Other Fin. Act. | $0 | -$1 | $13,760 | $1 |
| Financing Cash Flow | $708,472 | $680,160 | $627,985 | -$71,922 |
| Forex Effect | $158,574 | $125,000 | $213,710 | $14,209 |
| Net Chg. in Cash | -$2,553,427 | $234,453 | $2,422,448 | $11,480 |
| Supplemental Information | – | – | – | – |
| Beg. Cash | $6,517,007 | $6,282,554 | $3,860,106 | $3,848,626 |
| End Cash | $3,963,580 | $6,517,007 | $6,282,554 | $3,860,106 |
| Free Cash Flow | -$3,463,395 | -$427,482 | $1,566,683 | $76,205 |